ELSEVIER

Diabetes Research and Clinical Practice 67 (2005) 273–275

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 67

Acharya, G.P., see Sasaki, H. **67**, 167
Ahmed, N., Advanced glycation endproducts—role in pathology of diabetic complications **67**, 3
Ahn, C.W., see Kim, Y.M. **67**, 43
Airaksinen, K.E.J., see Luukinen, H. **67**, 163
Akazawa, S., see Sun, F. **67**, 110
Altun, A., see Ugur-Altun, B. **67**, 130
Ambye, L., S. Rasmussen, M. Fenger, T. Jørgensen, K. Borch-Johnsen, S. Madsbad, S.A. Urhammer, Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome **67**, 175
Amemiya, S., see Yokota, I. **67**, 227
Ang, L.W., S. Ma, J. Cutter, S.K. Chew, C.E. Tan, E.S. Tai, The metabolic syndrome in Chinese, Malays and Asian Indians, Factor analysis of data from the 1998 Singapore National Health Survey **67**, 53
Atar, M., see Puder, J.J. **67**, 119
Atsumi, Y., see Suzuki, Y. **67**, 92

Bando, Y., see Ota, T. **67**, 63
Bearne, A., see Currie, C.J. **67**, 144
Borch-Johnsen, K., see Ambye, L. **67**, 175
Botta, R., see Napoli, A. **67**, 267
Boyer, M.-C., see Favier, F. **67**, 234

Cederholm, J., B. Eliasson, P.M. Nilsson, L. Weiss, S. Gudbjörnsdottir, for the Steering Committee of the Swedish National Diabetes Register, Microalbuminuria and risk factors in type 1 and type 2 diabetic patients **67**, 258
Cha, B.S., see Kim, Y.M. **67**, 43
Chen, C.-H., see Hsieh, C.-J. **67**, 78
Chen, J.-F., see Hsieh, C.-J. **67**, 78
Chew, S.K., see Ang, L.W. **67**, 53
Chien, W.-Y., see Hsieh, C.-J. **67**, 78
Cho, S.-Y., see Lee, M.-K. **67**, 22
Choi, M.-S., see Lee, M.-K. **67**, 22
Choi, S.H., see Kim, Y.M. **67**, 43
Cianni, G.D., see Napoli, A. **67**, 267
Colatrella, A., see Napoli, A. **67**, 267
Currie, C.J., C.L. Morgan, S. Dixon, P. McEwan, N. Marchant, A. Bearne, P. Sharplin, J.R. Peters, The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications **67**, 144
Cutter, J., see Ang, L.W. **67**, 53

Debussche, X., see Favier, F. **67**, 234
Dixon, S., see Currie, C.J. **67**, 144

Eddouks, M., A. Lemhadri, N.A. Zeggwagh, J.-B. Michel, Potent hypoglycaemic activity of the aqueous extract of *Chamaemelum nobile* in normal and streptozotocin-induced diabetic rats **67**, 189
Eguchi, K., see Sun, F. **67**, 110
Eliasson, B., see Cederholm, J. **67**, 258

Favier, F., I. Jaussent, N.L. Moullec, X. Debussche, M.-C. Boyer, J.-C. Schwager, L. Papoz, The REIDA Study Group, Prevalence of Type 2 diabetes and central adiposity in La Réunion Island, the REDIA Study **67**, 234
Fenger, M., see Ambye, L. **67**, 175
Fresa, R., see Napoli, A. **67**, 267
Fujimiya, M., see Tsujinaka, K. **67**, 99

Gallagher, A., P.D. Home, The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes **67**, 196
Gamba, S., see Napoli, A. **67**, 267
Gudbjörnsdottir, S., see Cederholm, J. **67**, 258

Hatano, M., see Yamasaki, Y. **67**, 204
Hayaishi-Okano, R., see Yamasaki, Y. **67**, 204
Hedley, A.J., see Thomas, G.N. **67**, 251
Hiltunen, L., see Renko, A.-K. **67**, 84
Hishikawa, Y., see Sun, F. **67**, 110
Ho, S.-Y., see Thomas, G.N. **67**, 251
Home, P.D., see Gallagher, A. **67**, 196
Homma, T., see Matsushita, Y. **67**, 220
Hori, M., see Yamasaki, Y. **67**, 204
Hsieh, C.-J., P.-W. Wang, R.-T. Liu, S.-C. Tung, W.-Y. Chien, J.-F. Chen, C.-H. Chen, M.-C. Kuo, Y.-H. Hu, Orlistat for obesity: benefits beyond weight loss **67**, 78
Hu, Y.-H., see Hsieh, C.-J. **67**, 78
Huh, K.B., see Kim, Y.M. **67**, 43
Hung, N.T.K., see Son, L.N.T.D. **67**, 243

Iizuka, Y., see Kikuchi, H. **67**, 137
Italia, S., see Napoli, A. **67**, 267
Itoh, K., see Sasaki, H. **67**, 167
Iwamoto, Y., see Watanabe, C. **67**, 180
Iwata, M., see Watanabe, C. **67**, 180
Janus, E.D., see Thomas, G.N. **67**, 251

doi:10.1016/S0168-8227(05)00020-3

Jaussent, I., see Favier, F. **67**, 234
Jørgensen, T., see Ambye, L. **67**, 175
Jung, C.-H., see Lee, W.-Y. **67**, 70
Jung, U.J., see Lee, M.-K. **67**, 22

Kajimoto, Y., see Yamasaki, Y. **67**, 204
Kakihana, K., see Kikuchi, H. **67**, 137
Kamihira, S., see Sun, F. **67**, 110
Kaplan, R.A., see Kendall, D.M. **67**, 29
Karsidag, K., see Karsidag, S. **67**, 211
Karsidag, S., S. Moralı, M. Sargın, S. Salman, K. Karsidag, O. Us, The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus **67**, 211
Kashiwagi, A., see Tsujinaka, K. **67**, 99
Katakami, N., see Yamasaki, Y. **67**, 204
Kawahara, K., see Matsushita, Y. **67**, 220
Kawai, K., see Kikuchi, H. **67**, 137
Kawakami, Y., see Kikuchi, H. **67**, 137
Kawasaki, E., see Sun, F. **67**, 110
Kawasaki, T., see Sasaki, H. **67**, 167
Keinänen-Kiukaanniemi, S., see Renko, A.-K. **67**, 84
Keller, U., see Puder, J.J. **67**, 119
Kendall, D.M., R.A. Kaplan, C.F. Paulson, J.L. Parkes, A.M. Tideman, Accuracy and utility of a 10-test disk blood glucose meter **67**, 29
Kida, K., see Yokota, I. **67**, 227
Kikuchi, H., Y. Kawakami, K. Kakihana, K. Kawai, Y. Murayama, Y. Iizuka, S. Suzuki, H. Suzuki, H. Sone, H. Toyoshima, H. Shimano, N. Yamada, Plasma chloride concentration as a new diagnostic indicator of insulin insufficiency **67**, 137
Kim, D.J., see Kim, Y.M. **67**, 43
Kim, K.R., see Kim, Y.M. **67**, 43
Kim, M.-J., see Lee, M.-K. **67**, 22
Kim, S.K., see Kim, Y.M. **67**, 43
Kim, S.-W., see Lee, W.-Y. **67**, 70
Kim, Y.M., B.S. Cha, D.J. Kim, S.H. Choi, S.K. Kim, C.W. Ahn, S.-K. Lim, K.R. Kim, K.B. Huh, H.C. Lee, Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus **67**, 43
Kobayashi, H., see Watanabe, C. **67**, 180
Kobayashi, S., see Sasaki, H. **67**, 167
Kogure, A., see Takakura, Y. **67**, 36
Koji, T., see Sun, F. **67**, 110
Kosaka, K., M. Noda, T. Kuzuya, Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males **67**, 152
Kosugi, K., see Yamasaki, Y. **67**, 204
Kudo, M., see Tsujinaka, K. **67**, 99
Kunii, D., see Son, L.N.T.D. **67**, 243
Kuo, M.-C., see Hsieh, C.-J. **67**, 78
Kuzuya, T., see Kosaka, K. **67**, 152

Laakso, M., see Renko, A.-K. **67**, 84
Lam, K.S.L., see Thomas, G.N. **67**, 251
Lam, T.H., see Thomas, G.N. **67**, 251
Lapolla, A., see Napoli, A. **67**, 267
Lee, H.C., see Kim, Y.M. **67**, 43
Lee, M.-K., M.-J. Kim, S.-Y. Cho, S.A. Park, K.-K. Park, U.J. Jung, H.-M. Park, M.-S. Choi, Hypoglycemic effect of Du-zhong (*Eucommia ulmoides* Oliv.) leaves in streptozotocin-induced diabetic rats **67**, 22
Lee, W.-Y., C.-H. Jung, J.-S. Park, E.-J. Rhee, S.-W. Kim, Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III **67**, 70
Leksell, J.K., K.F. Wikblad, G.E. Sandberg, Sense of coherence and power among people with blindness caused by diabetes **67**, 124
Lemhadri, A., see Eddouks, M. **67**, 189
Lim, S.-K., see Kim, Y.M. **67**, 43
Liu, R.-T., see Hsieh, C.-J. **67**, 78
Luukinen, H., K.E.J. Airaksinen, Orthostatic hypotension predicts vascular death in older diabetic patients **67**, 163

Ma, S., see Ang, L.W. **67**, 53
Madsbad, S., see Ambye, L. **67**, 175
Maegawa, H., see Tsujinaka, K. **67**, 99
Mannino, D., see Napoli, A. **67**, 267
Marchant, N., see Currie, C.J. **67**, 144
Matsuhisa, M., see Yamasaki, Y. **67**, 204
Matsuoka, K., see Suzuki, Y. **67**, 92
Matsushita, Y., T. Yokoyama, T. Homma, H. Tanaka, K. Kawahara, Relationship between the ability to recognize energy intake and expenditure, and blood sugar control in type 2 diabetes mellitus patients **67**, 220
Matsuura, N., see Yokota, I. **67**, 227
McEwan, P., see Currie, C.J. **67**, 144
Michel, J.-B., see Eddouks, M. **67**, 189
Moralı, S., see Karsidag, S. **67**, 211
Morgan, C.L., see Currie, C.J. **67**, 144
Moullec, N.L., see Favier, F. **67**, 234
Muller, B., see Puder, J.J. **67**, 119
Muramatsu, T., see Suzuki, Y. **67**, 92
Murayama, Y., see Kikuchi, H. **67**, 137

Nagai, Y., see Ota, T. **67**, 63
Nakamura, T., see Tsujinaka, K. **67**, 99
Napoli, A., A. Colatrella, R. Botta, G.D. Cianni, R. Fresa, S. Gamba, S. Italia, D. Mannino, I. Piva, C. Suraci, L. Tonutti, E. Torlone, C. Tortul, A. Lapolla, Italian Diabetic Pregnancy Study Group (STD), Contraception in diabetic women: an Italian study **67**, 267
Nilsson, P.M., see Cederholm, J. **67**, 258
Nishimaki, K., see Suzuki, Y. **67**, 92
Nishio, Y., see Tsujinaka, K. **67**, 99
Noda, M., see Kosaka, K. **67**, 152

Ogaki, T., see Sasaki, H. **67**, 167
Ohta, S., see Suzuki, Y. **67**, 92
Oishi, T., see Watanabe, C. **67**, 180
Ota, T., T. Takamura, Y. Nagai, Y. Bando, R. Usuda, Significance of IA-2 antibody in Japanese type 1 diabetes: its association with GAD antibody **67**, 63

Papoz, L., see Favier, F. **67**, 234
Park, H.-M., see Lee, M.-K. **67**, 22
Park, J.-S., see Lee, W.-Y. **67**, 70
Park, K.-K., see Lee, M.-K. **67**, 22
Park, S.A., see Lee, M.-K. **67**, 22

Parkes, J.L., see Kendall, D.M. **67**, 29
Paulson, C.F., see Kendall, D.M. **67**, 29
Pavan, M., see Puder, J.J. **67**, 119
Peters, J.R., see Currie, C.J. **67**, 144
Piva, I., see Napoli, A. **67**, 267
Puder, J.J., M. Atar, B. Muller, M. Pavan, U. Keller, Using insulin pen needles up to five times does not affect needle tip shape nor increase pain intensity **67**, 119

Rajala, U., see Renko, A.-K. **67**, 84
Rasmussen, S., see Ambye, L. **67**, 175
Renko, A.-K., L. Hiltunen, M. Laakso, U. Rajala, S. Keinänen-Kiukaanniemi, The relationship of glucose tolerance to sleep disorders and daytime sleepiness **67**, 84
Rhee, E.-J., see Lee, W.-Y. **67**, 70

Sakai, T., see Son, L.N.T.D. **67**, 243
Salman, S., see Karsidag, S. **67**, 211
Sandberg, G.E., see Leksell, J.K. **67**, 124
Sargın, M., see Karsidag, S. **67**, 211
Sasaki, H., T. Kawasaki, T. Ogaki, S. Kobayashi, K. Itoh, Y. Yoshimizu, S. Sharma, G.P. Acharya, The prevalence of diabetes mellitus and impaired fasting glucose/glycaemia (IFG) in sub-urban and rural Nepal—the communities-based cross-sectional study during the democratic movements in 1990 **67**, 167
Sasaki, K., see Watanabe, C. **67**, 180
Sasaki, N., see Yokota, I. **67**, 227
Sato, A., see Watanabe, C. **67**, 180
Sato, T., see Watanabe, C. **67**, 180
Schwager, J.-C., see Favier, F. **67**, 234
Sharma, S., see Sasaki, H. **67**, 167
Sharplin, P., see Currie, C.J. **67**, 144
Shimano, H., see Kikuchi, H. **67**, 137
Son, L.N.T.D., D. Kunii, N.T.K. Hung, T. Sakai, S. Yamamoto, The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City **67**, 243
Sone, H., see Kikuchi, H. **67**, 137
Sugahara, K., see Sun, F. **67**, 110
Sun, F., E. Kawasaki, S. Akazawa, Y. Hishikawa, K. Sugahara, S. Kamihira, T. Koji, K. Eguchi, Apoptosis and its pathway in early post-implantation embryos of diabetic rats **67**, 110
Suraci, C., see Napoli, A. **67**, 267
Suzuki, H., see Kikuchi, H. **67**, 137
Suzuki, S., see Kikuchi, H. **67**, 137
Suzuki, Y., Y. Atsumi, K. Matsuoka, K. Nishimaki, S. Ohta, M. Taniyama, T. Muramatsu, Mitochondrial $tRNA^{Leu(UUR)}$ mutation at position 3243 detected in patients with type 1 diabetes **67**, 92

Tai, E.S., see Ang, L.W. **67**, 53
Takakura, Y., K. Yoshioka, T. Umekawa, A. Kogure, H. Toda, T. Yoshikawa, T. Yoshida, Thr54 allele of the FABP2 gene affects resting metabolic rate and visceral obesity **67**, 36
Takamura, T., see Ota, T. **67**, 63
Takayama, S., see Watanabe, C. **67**, 180
Tan, C.E., see Ang, L.W. **67**, 53
Tanaka, H., see Matsushita, Y. **67**, 220
Taniyama, M., see Suzuki, Y. **67**, 92
Tatli, E., see Ugur-Altun, B. **67**, 130
Thomas, G.N., S.-Y. Ho, E.D. Janus, K.S.L. Lam, A.J. Hedley, T.H. Lam, for the Hong Kong Cardiovascular Risk factor Prevalence Study Steering Committee, The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population **67**, 251
Tideman, A.M., see Kendall, D.M. **67**, 29
Toda, H., see Takakura, Y. **67**, 36
Tonutti, L., see Napoli, A. **67**, 267
Torlone, E., see Napoli, A. **67**, 267
Tortul, C., see Napoli, A. **67**, 267
Tosaka, M., see Watanabe, C. **67**, 180
Toyoshima, H., see Kikuchi, H. **67**, 137
Tsujinaka, K., T. Nakamura, H. Maegawa, M. Fujimiya, Y. Nishio, M. Kudo, A. Kashiwagi, Diet high in lipid hydroperoxide by vitamin E deficiency induces insulin resistance and impaired insulin secretion in normal rats **67**, 99
Tugrul, A., see Ugur-Altun, B. **67**, 130
Tung, S.-C., see Hsieh, C.-J. **67**, 78

Uchigata, Y., see Watanabe, C. **67**, 180
Ugur-Altun, B., A. Altun, E. Tatli, A. Tugrul, Factors related to exercise capacity in asymptomatic middle-aged type 2 diabetic patients **67**, 130
Umekawa, T., see Takakura, Y. **67**, 36
Urhammer, S.A., see Ambye, L. **67**, 175
Us, O., see Karsidag, S. **67**, 211
Usuda, R., see Ota, T. **67**, 63

Wang, P.-W., see Hsieh, C.-J. **67**, 78
Watanabe, C., T. Oishi, T. Yamamoto, K. Sasaki, M. Tosaka, T. Sato, H. Kobayashi, S. Takayama, A. Sato, M. Iwata, Y. Uchigata, Y. Iwamoto, Chorea and Broca aphasia induced by diabetic ketoacidosis in a type 1 diabetic patient diagnosed as Moyamoya disease **67**, 180
Weiss, L., see Cederholm, J. **67**, 258
Wikblad, K.F., see Leksell, J.K. **67**, 124

Yamada, N., see Kikuchi, H. **67**, 137
Yamamoto, S., see Son, L.N.T.D. **67**, 243
Yamamoto, T., see Watanabe, C. **67**, 180
Yamasaki, Y., N. Katakami, R. Hayaishi-Okano, M. Matsuhisa, Y. Kajimoto, K. Kosugi, M. Hatano, M. Hori, α-Glucosidase inhibitor reduces the progression of carotid intima-media thickness **67**, 204
Yokota, I., S. Amemiya, K. Kida, N. Sasaki, N. Matsuura, The Japanese Study Group of Insulin Therapy for Childhood and Adolescent-Diabetes, Past 10-year status of insulin therapy for preschool-age Japanese children with type 1 diabetes **67**, 227
Yokoyama, T., see Matsushita, Y. **67**, 220
Yoshida, T., see Takakura, Y. **67**, 36
Yoshikawa, T., see Takakura, Y. **67**, 36
Yoshimizu, Y., see Sasaki, H. **67**, 167
Yoshioka, K., see Takakura, Y. **67**, 36

Zeggwagh, N.A., see Eddouks, M. **67**, 189

ELSEVIER

Diabetes Research and Clinical Practice 67 (2005) 276–281

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 67

Activated caspase-3; Early post-implantation embryo; Neural tube defects; Diabetes; Apoptosis; Bax; Bcl-2; Cytochrome c **67**, 110

Adiponectin; Obesity; Orlistat; C-reactive protein; Leptin **67**, 78

Adjusted resting metabolic rate; Fatty acid-binding protein 2 gene; Obesity; Polymorphism **67**, 36

Advanced glycation endproducts; Glycation; Hyperglycaemia; Diabetes mellitus; Aminoguanidine; Antioxidant **67**, 3

Ageing; Orthostatic hypotension; Diabetes mellitus **67**, 163

Alcohol; Smoking; Exercise; Family history; Education level; Metabolic syndrome **67**, 70

Aminoguanidine; Glycation; Advanced glycation endproducts; Hyperglycaemia; Diabetes mellitus; Antioxidant **67**, 3

Antioxidant; Glycation; Advanced glycation endproducts; Hyperglycaemia; Diabetes mellitus; Aminoguanidine **67**, 3

Apoptosis; Early post-implantation embryo; Neural tube defects; Diabetes; Bax; Bcl-2; Cytochrome c; Activated caspase-3 **67**, 110

Aqueous extract; *Chamaemelum nobile*; Hypoglycaemia; Streptozotocin; Oral administration; Blood glucose **67**, 189

Autoimmune thyroid disease; Islet cell autoantibodies; IA-2A; GADA; Type 1 diabetes **67**, 63

Bax; Early post-implantation embryo; Neural tube defects; Diabetes; Apoptosis; Bcl-2; Cytochrome c; Activated caspase-3 **67**, 110

Bcl-2; Early post-implantation embryo; Neural tube defects; Diabetes; Apoptosis; Bax; Cytochrome c; Activated caspase-3 **67**, 110

Blindness; Diabetes; SOC; Power **67**, 124

Blood glucose self-monitoring; Diabetes mellitus; Reagent strips; Patient satisfaction; Blood glucose **67**, 29

Blood glucose; *Chamaemelum nobile*; Hypoglycaemia; Streptozotocin; Aqueous extract; Oral administration **67**, 189

Blood glucose; Blood glucose self-monitoring; Diabetes mellitus; Reagent strips; Patient satisfaction **67**, 29

Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Blood pressure; Genetics; Polymorphism; Metabolic syndrome; Insulin resistance; PGC-1α; Gly482Ser **67**, 175

Body mass index; Diabetes; Microalbuminuria; Hypertension; Register **67**, 258

Broca aphasia; Chorea; Diabetic ketoacidosis (DKA); Moyamoya disease **67**, 180

C-reactive protein; Obesity; Orlistat; Leptin; Adiponectin **67**, 78

Cardiovascular disease; Blood pressure; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Chamaemelum nobile; Hypoglycaemia; Streptozotocin; Aqueous extract; Oral administration; Blood glucose **67**, 189

doi:10.1016/S0168-8227(05)00021-5

Chinese; Blood pressure; Cardiovascular disease; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Cholesterol; Blood pressure; Cardiovascular disease; Chinese; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Chorea; Broca aphasia; Diabetic ketoacidosis (DKA); Moyamoya disease **67**, 180

Contraception; Type 1 diabetes; Type 2 diabetes; Diabetic pregnancy **67**, 267

Costs; Diabetes; Macrovascular complications; Hospital **67**, 144

Cytochrome c; Early post-implantation embryo; Neural tube defects; Diabetes; Apoptosis; Bax; Bcl-2; Activated caspase-3 **67**, 110

Daytime sleepiness; Habitual snoring; Sleep apnea; Type 2 diabetes; Depression **67**, 84

Depression; Habitual snoring; Sleep apnea; Daytime sleepiness; Type 2 diabetes **67**, 84

Diabetes mellitus; Blood glucose self-monitoring; Reagent strips; Patient satisfaction; Blood glucose **67**, 29

Diabetes mellitus; Glycation; Advanced glycation endproducts; Hyperglycaemia; Aminoguanidine; Antioxidant **67**, 3

Diabetes mellitus; Impaired fasting glucose/glycaemia (IFG); Prevalence; Nepal **67**, 167

Diabetes mellitus; Insulin; Needles; Lipodystrophy **67**, 119

Diabetes mellitus; Metabolic syndrome X; Insulin resistance; Hypertension; Lipids; Factor analysis **67**, 53

Diabetes mellitus; Obesity; La Réunion Island **67**, 234

Diabetes mellitus; Orthostatic hypotension; Ageing **67**, 163

Diabetes; Blindness; SOC; Power **67**, 124

Diabetes; Du-zhong (*Eucommia ulmoides* Oliv.); Insulin; Immunohistochemistry **67**, 22

Diabetes; Early post-implantation embryo; Neural tube defects; Apoptosis; Bax; Bcl-2; Cytochrome c; Activated caspase-3 **67**, 110

Diabetes; Macrovascular complications; Costs; Hospital **67**, 144

Diabetes; Microalbuminuria; Hypertension; Body mass index; Register **67**, 258

Diabetic ketoacidosis (DKA); Chorea; Broca aphasia; Moyamoya disease **67**, 180

Diabetic pregnancy; Type 1 diabetes; Type 2 diabetes; Contraception **67**, 267

Dietary therapy; Energy intake; Energy expenditure; Type 2 diabetes mellitus; Self estimation **67**, 220

Du-zhong (*Eucommia ulmoides* Oliv.); Diabetes; Insulin; Immunohistochemistry **67**, 22

Dyslipidaemia; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Guidelines; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Early post-implantation embryo; Neural tube defects; Diabetes; Apoptosis; Bax; Bcl-2; Cytochrome c; Activated caspase-3 **67**, 110

Education level; Smoking; Alcohol; Exercise; Family history; Metabolic syndrome **67**, 70

Electrophysiological study; Type 1 Diabetes Mellitus; Subclinical neuropathy **67**, 211

Energy expenditure; Energy intake; Dietary therapy; Type 2 diabetes mellitus; Self estimation **67**, 220

Energy intake; Energy expenditure; Dietary therapy; Type 2 diabetes mellitus; Self estimation **67**, 220

Ethnicity; Rosiglitazone; Thiazolidinedione; Insulin resistance; Type 2 diabetes mellitus **67**, 43

Exercise capacity; Type 2 diabetes; Exercise test; Insulin resistance **67**, 130

Exercise test; Type 2 diabetes; Exercise capacity; Insulin resistance **67**, 130

Exercise; Smoking; Alcohol; Family history; Education level; Metabolic syndrome **67**, 70

Factor analysis; Metabolic syndrome X; Insulin resistance; Hypertension; Diabetes mellitus; Lipids **67**, 53

Family history; Smoking; Alcohol; Exercise; Education level; Metabolic syndrome **67**, 70

Fatty acid-binding protein 2 gene; Obesity; Polymorphism; Adjusted resting metabolic rate **67**, 36

GADA; Islet cell autoantibodies; IA-2A; Type 1 diabetes; Autoimmune thyroid disease **67**, 63

Genetics; Polymorphism; Metabolic syndrome; Insulin resistance; Blood pressure; PGC-1α; Gly482Ser **67**, 175

α-Glucosidase inhibitor; Intima-media thickness; Post-prandial hyperglycemia **67**, 204

Gly482Ser; Genetics; Polymorphism; Metabolic syndrome; Insulin resistance; Blood pressure; PGC-1α **67**, 175

Glycation; Advanced glycation endproducts; Hyperglycaemia; Diabetes mellitus; Aminoguanidine; Antioxidant **67**, 3

Guidelines; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Hypertension; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Habitual snoring; Sleep apnea; Daytime sleepiness; Type 2 diabetes; Depression **67**, 84

Ho Chi Minh City; Metabolic syndrome; Prevalence; Risk factor; Urban population **67**, 243

Hospital; Diabetes; Macrovascular complications; Costs **67**, 144

Hyperglycaemia; Glycation; Advanced glycation endproducts; Diabetes mellitus; Aminoguanidine; Antioxidant **67**, 3

Hypertension; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Metabolic syndrome; Obesity; Type 2 diabetes mellitus **67**, 251

Hypertension; Diabetes; Microalbuminuria; Body mass index; Register **67**, 258

Hypertension; Metabolic syndrome X; Insulin resistance; Diabetes mellitus; Lipids; Factor analysis **67**, 53

Hypoglycaemia; *Chamaemelum nobile*; Streptozotocin; Aqueous extract; Oral administration; Blood glucose **67**, 189

Hypoglycemia; Type 1 diabetes; Japanese children; Preschool age; Insulin regimen **67**, 227

IA-2A; Islet cell autoantibodies; GADA; Type 1 diabetes; Autoimmune thyroid disease **67**, 63

Immunohistochemistry; Du-zhong (*Eucommia ulmoides* Oliv.); Diabetes; Insulin **67**, 22

Impaired fasting glucose/glycaemia (IFG); Diabetes mellitus; Prevalence; Nepal **67**, 167

Impaired glucose tolerance; Prevention; Type 2 diabetes; Lifestyle intervention; Japanese **67**, 152

Insulin aspart; Type 2 diabetes; Post-prandial hyperglycaemia; Lipids **67**, 196

Insulin regimen; Type 1 diabetes; Japanese children; Preschool age; Hypoglycemia **67**, 227

Insulin resistance; Genetics; Polymorphism; Metabolic syndrome; Blood pressure; PGC-1α; Gly482Ser **67**, 175

Insulin resistance; Lipid peroxide; Insulin secretion; IRS-1; NF-κB **67**, 99

Insulin resistance; Metabolic syndrome X; Hypertension; Diabetes mellitus; Lipids; Factor analysis **67**, 53

Insulin resistance; Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus; Ethnicity **67**, 43

Insulin resistance; Type 2 diabetes; Exercise test; Exercise capacity **67**, 130

Insulin secretion; Lipid peroxide; Insulin resistance; IRS-1; NF-κB **67**, 99

Insulin therapy; Plasma chloride; Type 2 diabetes **67**, 137

Insulin; Du-zhong (*Eucommia ulmoides* Oliv.); Diabetes; Immunohistochemistry **67**, 22

Insulin; Needles; Lipodystrophy; Diabetes mellitus **67**, 119

Intima-media thickness; α-Glucosidase inhibitor; Post-prandial hyperglycemia **67**, 204

IRS-1; Lipid peroxide; Insulin resistance; Insulin secretion; NF-κB **67**, 99

Islet cell autoantibodies; IA-2A; GADA; Type 1 diabetes; Autoimmune thyroid disease **67**, 63

Japanese children; Type 1 diabetes; Preschool age; Insulin regimen; Hypoglycemia **67**, 227

Japanese; Prevention; Type 2 diabetes; Lifestyle intervention; Impaired glucose tolerance **67**, 152

La Réunion Island; Diabetes mellitus; Obesity **67**, 234

Leptin; Obesity; Orlistat; C-reactive protein; Adiponectin **67**, 78

Lifestyle intervention; Prevention; Type 2 diabetes; Japanese; Impaired glucose tolerance **67**, 152

Lipid peroxide; Insulin resistance; Insulin secretion; IRS-1; NF-κB **67**, 99

Lipids; Metabolic syndrome X; Insulin resistance; Hypertension; Diabetes mellitus; Factor analysis **67**, 53

Lipids; Type 2 diabetes; Insulin aspart; Post-prandial hyperglycaemia **67**, 196

Lipodystrophy; Insulin; Needles; Diabetes mellitus **67**, 119

Macrovascular complications; Diabetes; Costs; Hospital **67**, 144

Maternal inheritance; Mitochondrial diabetes; 3243 Mitochondrial tRNA mutation; Type 1 diabetes; Real-time PCR with a TaqMan Probe **67**, 92

Metabolic syndrome X; Insulin resistance; Hypertension; Diabetes mellitus; Lipids; Factor analysis **67**, 53

Metabolic syndrome; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Obesity; Type 2 diabetes mellitus **67**, 251

Metabolic syndrome; Genetics; Polymorphism; Insulin resistance; Blood pressure; PGC-1α; Gly482Ser **67**, 175

Metabolic syndrome; Prevalence; Risk factor; Urban population; Ho Chi Minh City **67**, 243

Metabolic syndrome; Smoking; Alcohol; Exercise; Family history; Education level **67**, 70

Microalbuminuria; Diabetes; Hypertension; Body mass index; Register **67**, 258

3243 Mitochondrial tRNA mutation; Mitochondrial diabetes; Type 1 diabetes; Maternal inheritance; Real-time PCR with a TaqMan Probe **67**, 92

Mitochondrial diabetes; 3243 Mitochondrial tRNA mutation; Type 1 diabetes; Maternal inheritance; Real-time PCR with a TaqMan Probe **67**, 92

Moyamoya disease; Chorea; Broca aphasia; Diabetic ketoacidosis (DKA) **67**, 180

Needles; Insulin; Lipodystrophy; Diabetes mellitus **67**, 119

Nepal; Diabetes mellitus; Impaired fasting glucose/glycaemia (IFG); Prevalence **67**, 167

Neural tube defects; Early post-implantation embryo; Diabetes; Apoptosis; Bax; Bcl-2; Cytochrome c; Activated caspase-3 **67**, 110

NF-κB; Lipid peroxide; Insulin resistance; Insulin secretion; IRS-1 **67**, 99

Obesity; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Type 2 diabetes mellitus **67**, 251

Obesity; Diabetes mellitus; La Réunion Island **67**, 234

Obesity; Fatty acid-binding protein 2 gene; Polymorphism; Adjusted resting metabolic rate **67**, 36

Obesity; Orlistat; C-reactive protein; Leptin; Adiponectin **67**, 78

Oral administration; *Chamaemelum nobile*; Hypoglycaemia; Streptozotocin; Aqueous extract; Blood glucose **67**, 189

Orlistat; Obesity; C-reactive protein; Leptin; Adiponectin **67**, 78

Orthostatic hypotension; Diabetes mellitus; Ageing **67**, 163

Patient satisfaction; Blood glucose self-monitoring; Diabetes mellitus; Reagent strips; Blood glucose **67**, 29

PGC-1α; Genetics; Polymorphism; Metabolic syndrome; Insulin resistance; Blood pressure; Gly482Ser **67**, 175

Plasma chloride; Insulin therapy; Type 2 diabetes **67**, 137

Polymorphism; Fatty acid-binding protein 2 gene; Obesity; Adjusted resting metabolic rate **67**, 36

Polymorphism; Genetics; Metabolic syndrome; Insulin resistance; Blood pressure; PGC-1α; Gly482Ser **67**, 175

Post-prandial hyperglycaemia; Type 2 diabetes; Insulin aspart; Lipids **67**, 196

Postprandial hyperglycemia; Intima-media thickness; α-Glucosidase inhibitor **67**, 204

Power; Diabetes; Blindness; SOC **67**, 124

Preschool age; Type 1 diabetes; Japanese children; Insulin regimen; Hypoglycemia **67**, 227

Prevalence; Diabetes mellitus; Impaired fasting glucose/glycaemia (IFG); Nepal **67**, 167

Prevalence; Metabolic syndrome; Risk factor; Urban population; Ho Chi Minh City **67**, 243

Prevention; Type 2 diabetes; Lifestyle intervention; Japanese; Impaired glucose tolerance **67**, 152

Reagent strips; Blood glucose self-monitoring; Diabetes mellitus; Patient satisfaction; Blood glucose **67**, 29

Real-time PCR with a TaqMan Probe; Mitochondrial diabetes; 3243 Mitochondrial tRNA mutation; Type 1 diabetes; Maternal inheritance **67**, 92

Register; Diabetes; Microalbuminuria; Hypertension; Body mass index **67**, 258

Risk factor; Metabolic syndrome; Prevalence; Urban population; Ho Chi Minh City **67**, 243

Rosiglitazone; Thiazolidinedione; Insulin resistance; Type 2 diabetes mellitus; Ethnicity **67**, 43

Self estimation; Energy intake; Energy expenditure; Dietary therapy; Type 2 diabetes mellitus **67**, 220

Sleep apnea; Habitual snoring; Daytime sleepiness; Type 2 diabetes; Depression **67**, 84

Smoking; Alcohol; Exercise; Family history; Education level; Metabolic syndrome **67**, 70

SOC; Diabetes; Blindness; Power **67**, 124

Streptozotocin; *Chamaemelum nobile*; Hypoglycaemia; Aqueous extract; Oral administration; Blood glucose **67**, 189

Subclinical neuropathy; Type 1 Diabetes Mellitus; Electrophysiological study **67**, 211

Thiazolidinedione; Rosiglitazone; Insulin resistance; Type 2 diabetes mellitus; Ethnicity **67**, 43

Type 1 Diabetes Mellitus; Subclinical neuropathy; Electrophysiological study **67**, 211

Type 1 diabetes; Islet cell autoantibodies; IA-2A; GADA; Autoimmune thyroid disease **67**, 63

Type 1 diabetes; Japanese children; Preschool age; Insulin regimen; Hypoglycemia **67**, 227

Type 1 diabetes; Mitochondrial diabetes; 3243 Mitochondrial tRNA mutation; Maternal inheritance; Real-time PCR with a TaqMan Probe **67**, 92

Type 1 diabetes; Type 2 diabetes; Contraception; Diabetic pregnancy **67**, 267

Type 2 diabetes mellitus; Blood pressure; Cardiovascular disease; Chinese; Cholesterol; Dyslipidaemia; Guidelines; Hypertension; Metabolic syndrome; Obesity **67**, 251

Type 2 diabetes mellitus; Energy intake; Energy expenditure; Dietary therapy; Self estimation **67**, 220

Type 2 diabetes mellitus; Rosiglitazone; Thiazolidinedione; Insulin resistance; Ethnicity **67**, 43

Type 2 diabetes; Exercise test; Exercise capacity; Insulin resistance **67**, 130

Type 2 diabetes; Habitual snoring; Sleep apnea; Daytime sleepiness; Depression **67**, 84

Type 2 diabetes; Insulin aspart; Post-prandial hyperglycaemia; Lipids **67**, 196

Type 2 diabetes; Plasma chloride; Insulin therapy **67**, 137

Type 2 diabetes; Prevention; Lifestyle intervention; Japanese; Impaired glucose tolerance **67**, 152

Type 2 diabetes; Type 1 diabetes; Contraception; Diabetic pregnancy **67**, 267

Urban population; Metabolic syndrome; Prevalence; Risk factor; Ho Chi Minh City **67**, 243